Skip to content

Study · Systematic review · 2026

8 results

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

Azam MH, Azam MH, Azam KU, Azam MA, Afridi MK, Waqas SA, Abbas MS, Aminpoor H, Ahmed R

Diabetes, obesity & metabolism10 Mar 2026Cited by 2 (Europe PMC)

PMID41804840 (opens in a new tab)DOI10.1111/dom.70643 (opens in a new tab)PepBankPUB-41804840
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, mazdutide reduced percentage body weight (mean difference -12.42%).

    In plain wordsIn adults with obesity and no diabetes, mazdutide lowered body weight in pooled trials.

    Peptide
    Mazdutide
    Outcome
    DecreasePercent body weight change
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in body weight
    −12.42%
    pooled

    Source sentences

    Summary
    Mazdutide significantly reduced percentage body weight (MD = -12.42%, 95% CI: -16.15% to -8.68%), absolute body weight (MD = -9.76 kg, 95% CI: -13.15 to -6.37 kg) and waist circumference (MD = -7.98 cm, 95% CI: -10.24 to -5.72 cm).
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.
  2. 02HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, mazdutide reduced absolute body weight (mean difference -9.76 kg).

    In plain wordsIn adults with obesity and no diabetes, mazdutide lowered body weight in kilograms in pooled trials.

    Peptide
    Mazdutide
    Outcome
    DecreaseAbsolute body weight change
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in body weight
    −9.76 kg
    pooled

    Source sentences

    Summary
    Mazdutide significantly reduced percentage body weight (MD = -12.42%, 95% CI: -16.15% to -8.68%), absolute body weight (MD = -9.76 kg, 95% CI: -13.15 to -6.37 kg) and waist circumference (MD = -7.98 cm, 95% CI: -10.24 to -5.72 cm).
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.
  3. 03HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, mazdutide reduced waist circumference (mean difference -7.98 cm).

    In plain wordsIn adults with obesity and no diabetes, mazdutide reduced waist size in pooled trials.

    Peptide
    Mazdutide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in waist circumference
    −7.98 cm
    pooled

    Source sentences

    Summary
    Mazdutide significantly reduced percentage body weight (MD = -12.42%, 95% CI: -16.15% to -8.68%), absolute body weight (MD = -9.76 kg, 95% CI: -13.15 to -6.37 kg) and waist circumference (MD = -7.98 cm, 95% CI: -10.24 to -5.72 cm).
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.
  4. 04HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, systolic blood pressure decreased with mazdutide (mean difference -7.68 mmHg).

    In plain wordsIn adults with obesity and no diabetes, systolic blood pressure fell with mazdutide in pooled trials.

    Peptide
    Mazdutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference in systolic blood pressure
    −7.68 mmHg
    pooled

    Source sentences

    Summary
    Systolic blood pressure (MD = -7.68 mmHg), total cholesterol (MD = -0.57 mmol/L) and LDL (MD = -0.37 mmol/L) also decreased.
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.
  5. 05HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, total cholesterol decreased with mazdutide (mean difference -0.57 mmol/L).

    In plain wordsIn adults with obesity and no diabetes, total cholesterol fell with mazdutide in pooled trials.

    Peptide
    Mazdutide
    Outcome
    DecreaseTotal cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in total cholesterol
    −0.57 mmol/L
    pooled

    Source sentences

    Summary
    Systolic blood pressure (MD = -7.68 mmHg), total cholesterol (MD = -0.57 mmol/L) and LDL (MD = -0.37 mmol/L) also decreased.
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.
  6. 06HumanSystematic reviewEfficacy outcome

    In non-diabetic adults with obesity, LDL cholesterol decreased with mazdutide (mean difference -0.37 mmol/L).

    In plain wordsIn adults with obesity and no diabetes, LDL cholesterol fell with mazdutide in pooled trials.

    Peptide
    Mazdutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in LDL cholesterol
    −0.37 mmol/L
    pooled

    Source sentences

    Summary
    Systolic blood pressure (MD = -7.68 mmHg), total cholesterol (MD = -0.57 mmol/L) and LDL (MD = -0.37 mmol/L) also decreased.
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.
  7. 07HumanSystematic reviewSafety outcome

    In non-diabetic adults with obesity, adverse events were slightly more frequent with mazdutide (risk ratio 1.12).

    In plain wordsIn adults with obesity and no diabetes, side effects were slightly more common with mazdutide in pooled trials.

    Peptide
    Mazdutide
    Outcome
    IncreaseAdverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Risk ratio for adverse events
    1.12 ratio
    pooled

    Source sentences

    Summary
    Adverse events were slightly increased (RR = 1.12).
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.
  8. 08HumanSystematic reviewOther

    In non-diabetic adults with obesity, a dose-wise meta-regression of mazdutide trials showed significant effects (beta -0.99, p = 0.0187); the abstract does not name the outcome.

    In plain wordsIn adults with obesity and no diabetes, a pooled analysis of mazdutide trials found significant dose-related effects; the abstract does not say which outcome.

    Peptide
    Mazdutide
    Outcome
    Direction not reportedDose-wise meta-regression of effect
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Meta-regression beta
    −0.99 coefficient
    dose-wise

    Source sentences

    Summary
    Dose-wise meta-regression showed significant effects (β = -0.99, 95% CI: -1.81 to -0.16; p = 0.0187).
    1 context sentence
    Summary · context
    A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.